Company intelligence / Profile preview

AcuSphere Center

Ownership: Private
Development stage: Other

Overview

The company's lead product, Imagify™ (perflubutane polymer microspheres), was developed as a cardiovascular ultrasound contrast agent to evaluate myocardial perfusion and detect coronary artery disease. The company submitted both NDA and MAA filings but there is no evidence of commercial approval in the US/EU. No recent clinical results are available; the last major regulatory activity was in the late 2000s/early 2010s

Therapeutic areas: PulmonologyCardiovascularNeurology
Modalities: NanoparticleSmall moleculePolymer-drug conjugate therapy
Industry: Biotech

Beyond the preview

Go deeper on AcuSphere Center.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AcuSphere Center.

Explore the full profile